Vital Therapies Shares Up 18.8% on Insider Buying Activity (VTL)
Vital Therapies (NYSE:VTL) shares shot up 18.8% during mid-day trading on Thursday after an insider bought additional shares in the company, AR Network reports. The stock traded as high as $17.40 and last traded at $16.65, with a volume of 70,002 shares traded. The stock had previously closed at $14.01.
Specifically, Director Muneer A. Satter bought 14,500 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was purchased at an average price of $13.16 per share, with a total value of $190,820.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
VTL has been the subject of a number of recent research reports. Analysts at Bank of America initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set a “buy” rating on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set a “buy” rating and a $20.00 price target on the stock. Finally, analysts at William Blair initiated coverage on shares of Vital Therapies in a research note on Monday, May 12th. They set an “outperform” rating and a $28.00 price target on the stock.
The stock’s 50-day moving average is $12.37 and its 200-day moving average is $12.37. The company’s market cap is $352.6 million.
Vital Therapies (NYSE:VTL) last released its earnings data on Tuesday, June 3rd. The company reported ($24.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $23.95. Analysts expect that Vital Therapies will post $-2.47 EPS for the current fiscal year.
Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.